UBS Downgrades Ironwood Pharmaceuticals (IRWD) to Sell
Tweet
Share
E-mailGet Alerts IRWD Hot Sheet
Price: $4.31 +5.64%
Rating Summary:
11 Buy, 14 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 14 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
UBS downgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Neutral to Sell.
For an analyst ratings summary and ratings history on Ironwood Pharmaceuticals click here. For more ratings news on Ironwood Pharmaceuticals click here.
Shares of Ironwood Pharmaceuticals closed at $14.69 yesterday.
For an analyst ratings summary and ratings history on Ironwood Pharmaceuticals click here. For more ratings news on Ironwood Pharmaceuticals click here.
Shares of Ironwood Pharmaceuticals closed at $14.69 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- Wedbush Downgrades Globant S.A. (GLOB) to Neutral on balanced risk/reward
- JPMorgan Downgrades HomeCo Daily Needs REIT (HDN:AU) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
